Rethinking treatment for nervous system disorders
Empowering patients to live on their own terms

Who We Are

At its core, Eliem is motivated by the promise of helping people live happier, more fulfilling lives. The Eliem team channels its experience, energy and passion for improving patients’ quality of life by developing life-changing novel therapies for neuronal excitability disorders based on clinically validated mechanisms of action.

Our Approach: Optimizing Treatments for Neuronal Excitability Disorders

Tens of millions of people suffer from central and peripheral nervous system disorders, where an imbalance between excitation and inhibition has disrupted the homeostasis in affected neuronal networks. These disorders include a range of common conditions such as chronic pain, depression, epilepsy and anxiety. Currently available treatments for these conditions often fail to provide adequate control or relief, and they are often poorly tolerated, leaving people unable to live life on their own terms.

Developing improved treatments for patients requires a pragmatic and diligent approach. Equal parts rigorous and agile, the experienced Eliem team strives to make treatments that are more effective, safer and better tolerated than currently available treatments. Leveraging clinically validated mechanisms of action, we are moving steadily and efficiently to develop novel therapeutics for neuronal excitability disorders that deliver enhanced outcomes for patients.

Our Pipeline

Our two lead drug candidates have clinically validated mechanisms of action for neurological diseases and have demonstrated encouraging clinical and preclinical results. We are developing ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression and focal onset seizures. These compounds are designed to dramatically improve on the limitations of existing therapies with the potential to be best-in-class for these conditions with high unmet clinical needs.

Our Experienced Team

Eliem is founded and led by a team of seasoned industry executives who collectively bring decades of clinical development and biopharmaceutical commercialization experience to the company. The team not only shares an unparalleled determination and passion to help patients, but they also have a history of working together to successfully build companies and bring novel and effective therapies to market. Eliem is also advised by a Board with considerable neurology research and development experience and a strong track record of building successful companies.

The team’s combined expertise in neurological research, clinical development, commercialization and company building are critical for delivering on the promise of bringing innovative therapies to market to provide relief and hope for the millions of patients affected by neurological conditions.
Leadership Team
Board of Directors
Bob Azelby
President and Chief Executive Officer
Valerie Morisset, Ph.D.
Executive Vice President, R&D and Chief Scientific Officer
Erin Lavelle
Executive Vice President, Chief Operating Officer & Chief Financial Officer
James Bucher, J.D.
Executive Vice President & General Counsel
Mark Versavel, M.D., Ph.D., MBA
Interim Chief Medical Officer
Jo Palmer-Phillips, Ph.D.
Chief Development Officer
Susan Franks, MS
Senior Vice President/Head of Regulatory Affairs
Andrew Levin, M.D., Ph.D.
Bob Azelby
Judith Dunn, Ph.D.
Leone Patterson
Liam Ratcliffe, M.D., Ph.D.
Adam Rosenberg
Simon Tate


Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP)

Topline data from the Phase 2a clinical trial are expected in the third quarter of 2022 Virtual investor event to be held in July 2022 SEATTLE and CAMBRIDGE, United Kingdom, June 27, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc.  (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other
Load More


We are always looking to grow our team and believe it takes teamwork, trust and tenacity to deliver on the promise of helping patients live happier, more fulfilling lives. If this sounds like you, please indicate which position you are interested in and contact us at Careers US or Careers UK.

We’d love to connect.

Open Positions
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!
Sorry, there are currently no open positions available. Please check back soon!

Contact Us

Eliem Therapeutics, Inc.
23515 NE Novelty Hill Road, Suite B221 #125
Redmond, WA 98053

Eliem Therapeutics (UK) Ltd: Reg. 11893311
3rd Floor, 1 Ashley Road
Altrincham, Cheshire WA14 2DT